From routine bloodwork for a family dog to herd-level screening on a cattle farm, diagnostics now sit at the center of modern animal healthcare. According to Grand View Research, the global veterinary diagnostics market was valued at USD 8.4 billion in 2025 and is estimated at USD 9.3 billion in 2026. It is projected to reach USD 19.2 billion by 2033, growing at a CAGR of 11.0% from 2026 to 2033.

This post covers what is driving that growth, what is holding it back, who the major players are, and how the market breaks down.

Growth Drivers and Challenges

Growth Drivers

• Rising pet ownership and humanization: More households own pets, and owners increasingly treat them as family. In the U.S., nearly 94 million households owned pets in 2024, up from roughly 85 million in 2019, and over 57% of UK households owned pets. Higher spending on pet healthcare and wider pet insurance coverage make owners more willing to approve screening and early detection tests.
• Shift toward preventive care: Routine blood panels, screening tests and wellness checks are now standard in companion animal practice, which lifts recurring test volumes.
• Demand for faster, in-clinic results: Clinics handle heavy testing workloads (U.S. practices run around 90 million fecal tests a year), so point-of-care analyzers that cut turnaround time and ease workflow are gaining traction.
• Clinical guidelines calling for fuller workups: Structured, stepwise diagnostic pathways, such as the consensus statement on chronic inflammatory enteropathy in dogs, encourage greater use of lab tests, imaging and monitoring.
• Advances in molecular diagnostics: Genetic and protein-marker tests allow earlier, more precise detection in both companion and production animals.
• Livestock disease pressure: Cross-border livestock trade and recurring outbreaks, including Foot-and-Mouth Disease, sustain demand for reliable surveillance and testing to protect herd productivity and food safety.

Challenges

• Zoonotic and region-specific diseases: Transboundary threats such as avian influenza, Newcastle disease and swine influenza need continuous monitoring, and evolving strains complicate detection.
• Uneven infrastructure: Limited veterinary capacity and skilled staff in emerging economies and rural areas slow timely diagnosis.
• Cost and compliance: Advanced molecular platforms, biosecurity requirements and country-specific approvals raise costs and extend timelines for manufacturers and labs.
• Low-cost substitutes: In cost-sensitive settings, clinical examination, symptom-based treatment and basic rapid tests can displace high-end diagnostic systems.

Go Deeper! Want to see the data first? Download a free sample of the full Veterinary Diagnostics Market report.

Major Market Leaders

The industry is fragmented, with large, mid-sized and small players competing across regions and product lines. Companies profiled in the report include IDEXX Laboratories, Zoetis, Antech Diagnostics (Mars Inc.), Agrolabo S.p.A., Embark Veterinary, Esaote SPA, Thermo Fisher Scientific, Innovative Diagnostics SAS, Virbac and FUJIFILM Corporation.

• Strategies in play: Leaders invest in R&D, widen distribution, and partner with clinics, research institutions and regional players.
• Active M&A: In November 2025, Zoetis acquired Veterinary Pathology Group, a laboratory network across the UK and Ireland. In October 2025, OR Technology Group acquired Ireland's VetEquip Ltd.
• AI-led launches: Zoetis introduced Vetscan OptiCell in September 2024, an AI-enabled point-of-care hematology analyzer.
• Zoetis (mature player): Benefits from AI integration, broad distribution and strong brand recognition, but faces price erosion and regulatory complexity around AI-driven diagnostics.
• Thermo Fisher (emerging player): Targets white-space opportunities such as affordable, field-deployable PCR for livestock, though it trails incumbents in assay development pace and regulatory footprint.

Market Dynamics

• Innovation intensity: Portable devices, IT integration, rapid assays and AI-assisted image and data analysis are reshaping workflows.
• Consolidation: Partnerships and acquisitions help firms add technologies and portfolios, and enter new geographies.
• Regulation: In the U.S., certain kits fall under USDA APHIS oversight while some devices are regulated by the FDA. In Europe, the European Medicines Agency works with national authorities.
• Regional expansion: Firms tailor products to local regulatory and clinical needs as they enter emerging markets.

Need insights tailored to your business? Customize this report with additional regions, segments or data points.

Market Segmentation

The report segments the market by product, animal, testing category, end use and region.

• By product: Consumables, reagents and kits led with a 52.5% share in 2025 and is also the fastest-growing segment, thanks to recurring demand across hematology, biochemistry, urinalysis, serology and immunoassays. Equipment and instruments is the second fastest-growing, helped by point-of-care devices and imaging.
• By animal: Companion animals (dogs, cats, horses and others) led in 2025, driven by preventive and orthopedic diagnostics. Production animals (cattle, poultry, swine and others) is the fastest-growing as livestock labs expand serological and molecular testing.
• By testing category: Clinical chemistry led in 2025 through routine organ-function and metabolic screening. Cytopathology is growing fastest, as minimally invasive sampling such as fine needle aspiration is used more for tumors and infections. Other categories include microbiology, parasitology, histopathology, hematology, immunology and serology, imaging and molecular diagnostics.
• By end use: Veterinarians held the largest share in 2025, while animal owners and producers is the fastest-growing as point-of-care devices move testing to homes and farms. Reference laboratories complete the segmentation.
• By region: North America led with a 40.1% share in 2025, supported by established infrastructure, high disposable income and key players. Asia Pacific is the fastest-growing region, driven by rising pet ownership, awareness of pet health, demand for genetic testing and a large cattle population. Europe, Latin America and the Middle East and Africa also show steady growth.

The Road Ahead

Strong pet-care spending, tighter disease surveillance and rapid technology change point to sustained double-digit growth. Companies that combine fast point-of-care tools, molecular precision and AI-enabled analysis, backed by solid regional distribution, are best placed to capture the opportunity.

Explore our dedicated business services:

Prism AI: Market Intelligence with Cited Research- Ask questions in plain language and get insights drawn from Grand View Research's entire research library, with sources cited. Create your free account today.

U.S. Healthcare Facility Mapping & Intelligence Platform: Get facility-level intelligence to guide smarter decisions. Sign up Today